Genelux Corporation · NASDAQ:GNLX
Genelux — Investor Presentation (August 2024)
28 slides from Genelux's investor presentation, Aug 1, 2024
Slide 1: Redefining Immuno-Oncology: Corporate Presentation
@HeNeELUx Redefining Immuno-Oncology Corporate Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 of the Securities Exchange Act of 1934, ‘as amended, which are subject to the “safe harbor” created by those sections, about Ge
Slide 3: Genelux Has Executed on Multiple Milestones and is Positioned for the Future
Genelux Has Executed on Multiple Milestones and is Positioned for the Future Regular Cadence of Important Program Milestones starting 2H, 2024 Executed Milestones IN Extended runway past PRROC topline results — 2H, 2025 Syndicate of healthcare Topli Its expected é : i pline results expecte instituti
Slide 4: The Most Advanced Non-local Delivery Oncolytic Immunotherapy
The Most Advanced Non-local Delivery Oncolytic Immunotherapy Olvi-Vec: 7 Completed Clinical Trials (>150 Patients) Physician-preferred routes of delivery = Regional and Systemic Administration to preferentially locate, colonize and destroy tumor cells, including metastatic disease = IV therapy curre
Slide 5: Program Builds on Completed Trials to Exploit Competitive Advantages
Program Builds on Completed Trials to Exploit Competitive Advantages 3 Upcoming Trial Readouts have Potential to Redefine: > Therapy (platinum resensitization in multiple indications) > Modality (systemic administration of an oncolytic virus) ‘Systemic Route Indication Design Preclinical Collaborato
Slide 6: Olvi-Vec Seeks to Unleash Immune System Against Cancer
Olvi-Vec Seeks to Unleash Immune System Against Cancer Key Takeaways IN Olvi-Vec is being developed as a robust immune modulator that utilizes a triple mode of action to mount a personalized attack against cancer cells throughout the body and aims to: + Selectively replicate in tumors to kill cancer
Slide 7: Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance
Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance Olvi-Vec-Induced Hot Tumor Pro-therapeutic gene expression [VIRO-15 Monotherapy Data] Chemotherapy synergy Immunogenic cell death and > Positive regulation of T-cell activating E . presentation of oncogenic neoantigens and trafficking
Slide 8: A Maturing Modality with Phase Companies Validating OV Potential
A Maturing Modality with Phase 3 Companies Validating OV Potential ENELUX > Next Generation Regional & Systemic Administration Phase 2 Ovarian Cancer Phase Ib Solid Tumors Limitations of 1st Gen Viruses + Limited to local delivery and scope of addressable cancers Potential Clinical Advantages of Olv
Slide 9: Regional Administration Program: Ovarian Cancer
Regional - Administration GeneL_uxD> Program Ovarian Cancer
Slide 10: Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results
Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance. Primary Endpoint Progression-Free Survival Key Secondary Endpoints Key Inclusion Criteria Multi-center,
Slide 11: Ovarian Cancer Program Completed Clinical Trials
Ovarian Cancer Program Completed Clinical Trials Regional (intraperitoneal) delivery in heavily pre-treated Key Takeaways platinum resistant/refractory patients + Phase I/b tested condensed dosing schedule and demonstrated Trial Sites | Clinical ; , Design Patients | Randomization | Status tolerabil
Slide 12: Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy
Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy Heavily Pretreated Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer Data Presentations 1. 2020 Digital Annual Meeting of International Gynecologic Cancer Society + High-grade serous, endometrioid or clear-cell ovarian
Slide 13: Phase 2 Clinically Meaningful Responses in Heavily Pretreated Patients
Phase 2 Clinically Meaningful Responses in Heavily Pretreated Patients Key Clinical Takeaways iN Overall Response Rate (ORR) & Progression-Free Survival (PFS)* ORR by Duration of ORR by Medan Promising ORR and PFS, and RECIST1.1” Response CA125 survival (08) clinical reversal of platinum urvivall( r
Slide 14: Seeking to Reset Life Clock of Heavily Pre-treated Patients
Seeking to Reset Life Clock of Heavily Pre-treated Patients IN Key Clinical Takeaways Olvi-Vec addresses a broad and underserved pool of patients * Olvi-Vec trial inclusion criteria allows patients regardless of (i) tumor biomarkers, (ii) platinum refractory tumors, or (iii) number of prior lines of
Slide 15: Self Launch Olvi-Vec for Ovarian Cancer in the US
Self Launch Olvi-Vec for Ovarian Cancer in the US : Drivers of Market Penetration Partnerships Peay ifs Self-Manufacturing Patients Reimbursement Leverage partnership with GOG Foundation * Preeminent US-based cooperative group in Gynecologic Oncology * Composed of leading KOLs in the field * Partner
Slide 16: Systemic Administration Programs: Lung Cancers
Systemic —. <> Administration @ene_ux Programs Lung Cancers
Slide 17: The Future of Oncolytic Viruses
The Future of Oncolytic Viruses “Building on the promising data from Genelux, the systemic administration of Olvi-Vec introduces an ideal strategy for platinum resensitization in resistant tumors. I'm looking forward to the trial results in lung cancer, which could lead to significant breakthroughs
Slide 18: Systemic Administration Program
Systemic Administration Program Key Takeaways IN Ongoing and Planned Clinical Trials + Funding commitment by Newsoara of =a HitoUS bared concleiineaoo tule in sponeor | Tal stes Indeaton cinesisioge | Pa | rancomnton | stan RESIS Re it/plati Regulator us ecurrenvolatioum- | prose | -1gp ta egulatory
Slide 19: Systemic Administration Demonstrated Dose-dependent OS Benefit
Systemic Administration Demonstrated Dose-dependent OS Benefit Key Clinical Takeaways Demonstrated feasibility and clinical benefit of multiple IV cycles + Median 5 prior lines of therapy + Regimen: various dosing levels and schedules (typically over 4-6 months) + Well tolerated: no-MTD reached with
Slide 20: Systemic Administration + Chemo Generated Encouraging Data
Systemic Administration + Chemo Generated Encouraging Data 3 Cancer - AdventHealth | Institute - EXPanded Access Program Key Clinical Takeaways IN Platinum refractory metastatic High-grade pancreatic cancer with cervical cancer with lung mets lung & liver mets Pate ac Case Report (Pt #21406), ase Re
Slide 21: Phase 2 Trial in Recurrent Non-small Cell Lung Cancer
Phase 2 Trial in Recurrent Non-small Cell Lung Cancer Patients with Non-small Cell Lung Cancer after First Progression while on Front-Line Immune Checkpoint Inhibitor-based Maintenance Multi-center, randomized open-label =~142 Primary Endpoint Progression-Free Survival Key Inclusion Criteria Experim
Slide 22: Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer
Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer Heavily Pretreated Patients with Platinum-Relapse or Platinum-Refractory Small Cell Lung Cancer Phase 1b Endpoints " —_ . 7 Primary Endpoint Key Inclusion Criteria Multi-center, randomized open-label Safety and tolerability n=~110 + Prior failure
Slide 23: V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical
V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical VACT mh V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT. Key Trial Takeaways V2ACT Immunotherapy, Vaccination increases the numbers of neoantigen-s
Slide 24: Intellectual Property: Market Exclusivity & Freedom to Operate
Intellectual Property: Market Exclusivity & Freedom to Operate Patent Portfolio: 33 issued patents & 7 pending; Fl Olvi-Vec covered by Composition of Matter (2031*) + and Manufacturing (2038) Str g IP & Regulatory Designations ~~ Olvi-Vec: No third-party royalties due ye <2 Long Duration of Regulato
Slide 25: Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch
Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch Key Takeaways IN Facilities and Operations based in Southern California Headquarters Westlake + Large-scale manufacturing rocess + Capacity for clinical studies and commercial launch needs * Clinical Science capabilities to support
Slide 26: Accomplished Leadership Team
Accomplished Leadershi Team Executive Team Board of Directors THOMAS ZINDRICK, JD asset commis hoitman of the Board pk orsimessai JAMES L. TYREE, MBA Qo Lead Independent Director Slanvoee Thomas Zindrick, JD Lourie Zak Paul Scigalla, MD, PhD Sean Ryder, JD ifmner Chief Executive Officer Chief Financ
Slide 27: Genelux Has Executed on Multiple Milestones and is Positioned for the Future
Genelux Has Executed on Multiple Milestones and is Positioned for the Future Regular Cadence of Important Program Milestones starting 2H, 2024 Executed Milestones IN Extended runway past PRROC topline results — 2H, 2025 Syndicate of healthcare Topli Its expected é : i pline results expecte instituti
Slide 28: Redefining Immuno-Oncology
@HeNeELUx Redefining Immuno-Oncology Corporate Presentation